Literature DB >> 27057437

Get a grip on immune cells by inhibiting JAKs.

Kathrin Schönberg1, Janna Rudolph1, Sowmya Parampalli Yajnanarayana1, Dominik Wolf2.   

Abstract

JAK inhibitors are approved for myelofibrosis (MF) and polycythemia vera (PV), as they reverse inflammation-associated splenomegaly and symptoms. Notably, JAK inhibitors only marginally affect disease burden. The anti-inflammatory effects of JAK inhibitors affects DC, T and NK cells explaining their therapeutic potential for limitation of cancer-associated inflammation, Graft-versus-Host Disease (GvHD) and autoimmunity.

Entities:  

Year:  2015        PMID： 27057437      PMCID： PMC4801466          DOI： 10.1080/2162402X.2015.1071009

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.

Authors:  Roberto Bellucci; Hong-Nam Nguyen; Allison Martin; Stefan Heinrichs; Anna C Schinzel; William C Hahn; Jerome Ritz
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

2.  Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Authors:  Annkristin Heine; Peter Brossart; Dominik Wolf
Journal:  Blood       Date:  2013-11-28       Impact factor: 22.113

3.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Authors:  Sowmya Parampalli Yajnanarayana; Thomas Stübig; Isabelle Cornez; Haefaa Alchalby; Kathrin Schönberg; Janna Rudolph; Ioanna Triviai; Christine Wolschke; Annkristin Heine; Peter Brossart; Nicolaus Kröger; Dominik Wolf
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

Review 5.  The V617F JAK2 mutation and the myeloproliferative disorders.

Authors:  Melanie J Percy; Mary Frances McMullin
Journal:  Hematol Oncol       Date:  2005 Sep-Dec       Impact factor: 5.271

6.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Authors:  Silvia Spoerl; Nimitha R Mathew; Michael Bscheider; Annette Schmitt-Graeff; Sophia Chen; Tony Mueller; Mareike Verbeek; Julius Fischer; Vera Otten; Martina Schmickl; Kristina Maas-Bauer; Jürgen Finke; Christian Peschel; Justus Duyster; Hendrik Poeck; Robert Zeiser; Nikolas von Bubnoff
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

7.  JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Authors:  Kathrin Schönberg; Janna Rudolph; Maria Vonnahme; Sowmya Parampalli Yajnanarayana; Isabelle Cornez; Maryam Hejazi; Angela R Manser; Markus Uhrberg; Walter Verbeek; Steffen Koschmieder; Tim H Brümmendorf; Peter Brossart; Annkristin Heine; Dominik Wolf
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

8.  The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Solveig Nora Daecke; Stephanie Wallner; Sowmya Parampalli Yajnanarayana; Christian Kurts; Dominik Wolf; Peter Brossart
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

Review 9.  JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Anticancer Agents Med Chem       Date:  2012-11       Impact factor: 2.505
  9 in total
  1 in total

1.  The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.

Authors:  Martina Barone; Lucia Catani; Francesca Ricci; Marco Romano; Dorian Forte; Giuseppe Auteri; Daniela Bartoletti; Emanuela Ottaviani; Pier Luigi Tazzari; Nicola Vianelli; Michele Cavo; Francesca Palandri
Journal:  Oncoimmunology       Date:  2020-06-23       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.